June 24, 2025 — On the closing day of the ADA Scientific Sessions in Chicago, we got a good look at two remarkable new obesity drugs. Both of them have potential to bring important advances. Both of them need more work before they will be ready to go to FDA for approval. This was a rare treat. Bimagrumab The […]
June 22, 2025 — We are only halfway through ADA2025 in Chicago and already the flood of information about new drugs for obesity like orforglipron, amycretin, and a host of others leaves us feeling like we have been sprayed down by a fire hose. Much more will be coming at us in the next two days. Orforglipron and Other […]
June 13, 2025 — Thoughtful reporting by Jackie Snow in the New York Times prompts us to wonder about the possibility of a “contagion effect” from GLP-1s in families. When a parent receives highly effective treatment for obesity, what might the effect be on other family members? Of course, any answers to this question come from anecdotal observations. They […]
June 5, 2025 — Regeneron announced tantalizing results for the combination of trevogrumab with semaglutide for losing fat while preserving muscle. With the combination of these two drugs, it appears that individuals might lose more fat mass and less muscle mass than with semaglutide alone. In short, the promise is for a better quality of weight loss, leaving people […]
May 22, 2025 — The game is over. Today is the day legal semaglutide compounding at scale ends by decree from the FDA. Compounding pharmacies have known this day was coming since February when the agency determined that the shortage of semaglutide from Novo Nordisk was over. Well-informed patients who have depended upon compounding for affordable access to a […]
May 21, 2025 — We do not think for a minute that Lilly or Novo Nordisk will be pursuing any sort of mental health indication for semaglutide or tirzepatide. But it increasingly appears that the effect of GLP-1 use for either diabetes or obesity is more positive than negative for mental health. A new systematic review and meta-analysis in […]
May 13, 2025 — At ECO2025 today, a new analysis from the landmark SELECT trial reveals that heart health benefits with semaglutide can start early for people with obesity and pre-existing heart disease. Within just three months, semaglutide reduced the risk of major cardiovascular events (MACE) by 38% compared to placebo. By six months, this risk dropped by 41%. […]
May 12, 2025 — This is quite a day for the folks who have invested energy and others who have invested a great deal of money into developing tirzepatide for obesity. They took the risk of doing a head-to-head study of this drug against semaglutide and it clearly paid off. In the SURMOUNT-5 study, tirzepatide came out ahead on […]
May 3, 2025 — Rather quietly this week, Eli Lilly and Company announced that it had withdrawn an application to FDA for an indication to use tirzepatide (Zepbound) in treating heart failure – specifically for HFpEF. This news came up in a briefing for investors, with Lilly’s Chief Scientific Officer, Dan Skovronsky, saying: “Following discussions with the FDA, we’ve […]
May 1, 2025 — Late yesterday, the New England Journal of Medicine published interim results from a study that points to another breakthrough for semaglutide – this time for a MASH indication. The analysis includes 800 patients with MASH with an average BMI of 34.5. Only 22 patients in this trial had a BMI that indicated leanness. Nearly two […]
